Optimising malignant melanoma management in Europe
EUMelaReg collects health information to improve care and treatment for patients with skin cancer
Sustaining and fostering collaboration between academia and industry
for the collection of baseline, treatment and outcome data of representative samples of malignant melanoma patients of major European countries.
Building the largest and quickest melanoma registry in the world
EUMelaReg collects real-world data on melanoma patients throughout Europe and integrates them in a data warehouse.

EUMelaReg Project: Successful Poster Presentation at ASCO 2024

A significant proportion of patients with non-resectable melanoma treated with immune checkpoint inhibitors (ICI) achieve durable remissions, but there is limited data on the optimal duration of ICI therapy in these patients. In clinical trials the duration of ICI treatment was limited to a fixed maximum time regardless of the remission state. Therefore, the influence of the duration and maintenance of ICI therapy in patients with a partial (PR) or complete remission (CR) on further outcome is of interest.

Primary objectives of this study are progression-free and overall survival outcomes after achieving PR or CR in non-resectable stage III/IV melanoma patients in relation to the duration of maintenance treatment with ICIs after achieving the respective response.

The results of this study underpins the relevance of the depth of ICI-induced remissions for subsequent patient management. Thus, melanoma patients achieving a PR from first-line ICI benefit significantly from a continued maintenance treatment after achieving the response in terms of progression-free and overall survival. For patients with a CR there was no significant impact of the duration of maintenance treatment on further outcome. However, sample size restrictions warrant further research on which subgroups can safely been stopped after CR.

Poster Link: https://www.eumelareg.org/publications